Skip to main content
NIH funding notice RFA-AG-19-025

Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R43/R44 Clinical Trial Not Allowed)

Closed on March 8, 2019.

Posted
October 25, 2018
Close date
March 8, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $524,947 in first-year total cost, median $262,474.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 ETTN-P (13)]2

Most frequent institutions

  1. ISOPLEXIS, INC.1
  2. NORTIS, INC.1
Competing awards under RFA-AG-19-025 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Organ-on-chip based assays for personalized assessment of renal resilience in aging patients1R43AG066020-01NEUMANN, THOMASNORTIS, INC., WA$300,000ZRG1
2019Age-dependent Single-cell Metabolomic and Proteomic Profiling of Human Immune System1R43AG066022-01MCCONNELL, TIMOTHY SZHOU, JINGISOPLEXIS, INC., DE$224,947ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-AG-19-025: Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R43/R44 Clinical Trial Not Allowed) | ScienceDex | ConductScience